Thank you

You are now registered to receive site updates and information.

Register

Get the latest information on ambulatory glucose profile (AGP)
and news about glucose management.

ADC-01834 Ver 2.0 11/15
This site is intended for healthcare professionals only.
THIS SITE IS INTENDED FOR HCPs ONLY.
THIS SITE IS INTENDED FOR HCPs ONLY.

ABSTRACT

Episodic glucose monitoring—3 to 5 days is not enough

MORE INFO

DIABETES TECHNOLOGY & THERAPEUTICS

Volume 11, Number 3, 2011


Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring Xing et al

Intermittent short-term use (3–5 days) of blinded continuous glucose monitoring (CGM) technology continues to be used for retrospective adjustments in treatment regimens for type 1 diabetes (T1D). However, the optimal duration and frequency of such monitoring to accurately reflect long-term glycemic control have not been assessed.

Data from two 6-month randomized clinical trials and 6-month extension studies evaluating the effectiveness of real-time CGM in 451 intensively treated patients with T1D suggest:

  • Longer monitoring periods of 12–15-days every 3 months are needed to obtain an accurate assessment of overall glucose control.
  • Shorter periods of sampling can be useful, but the correlation with 3-month measures of glycemic control is lower.

ADC-02179 Ver 1.0 11/15

You are about to leave DiabetesFrontier.us

You are now leaving DiabetesFrontier.us. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

 

ADC-01837 Ver 2.0 11/15